NEWS

San Jose, CA – September 18, 2023 (PRESS RELEASE)

Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”)

Biomed Industries, Inc. (Biomed) announced today that its Chairman and CEO Lloyd L. Tran presented the Biomed’s latest research at the Neurology World Conference in Miami FL, held from September 15-17, 2023, entitled Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder.

This is the Company’s first major presentation of the results of its clinical trials of NA-831 for treatment of both Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD). It further validates Biomed’s breakthrough therapies based on the Neurogenesis Hypothesis, challenging current treatments that show little effect for AD with significant adverse events, and current treatments for MDD, also with significant adverse events.

The presentation focused on the results of the Company’s Phase 2A trial of NA-831 for AD and its Phase 1B trial for MDD, both of which showed positive patient outcomes with few, and minor, adverse events. Based on these studies, the Neurogenesis Hypothesis has been shown to be a viable approach for further research for Alzheimer’s disease (AD) and Major Depressive Disorder (MDD).

“With over 6 million patients suffering with Alzheimer’s Disease, with no effective treatment for them, coupled with 21 million patients in the US suffering with MDD, where current treatments come with severe adverse events, we are optimistic that the Neurogenesis approach can be a major breakthrough in treatment”, said Lloyd L. Tran, CEO of Biomed Industries. He continued: “as NA-831, a small molecule drug that easily crosses the blood-brain barrier, we are not seeing the toxicity and serious side effects with current treatments on the market.”

Biomed is in the process of conducting a Phase 2B AD trial and a Phase 3 MDD trial of NA-831 and will seek FDA approval of NA-831 for treatment of both AD and MDD.

About Biomed Industries, Inc.

Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer's disease and other neurological disorders. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com

CONTACT

Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com